Literature DB >> 23466706

Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy?

Sujata Choudhury1, Vamsi K Kolukula, Anju Preet, Chris Albanese, Maria Laura Avantaggiati.   

Abstract

One fundamental feature of mutant forms of p53 consists in their accumulation at high levels in tumors. At least in the case of neomorphic p53 mutations, which acquire oncogenic activity, stabilization is a driving force for tumor progression. It is well documented that p53 mutants are resistant to proteasome-dependent degradation compared with wild-type p53, but the exact identity of the pathways that affect mutant p53 stability is still debated. We have recently shown that macroautophagy (autophagy) provides a route for p53 mutant degradation during restriction of glucose. Here we further show that in basal conditions of growth, inhibition of autophagy with chemical inhibitors or by downregulation of the essential autophagic genes ATG1/Ulk1, Beclin-1 or ATG5, results in p53 mutant stabilization. Conversely, overexpression of Beclin-1 or ATG1/Ulk1 leads to p53 mutant depletion. Furthermore, we found that in many cell lines, prolonged inhibition of the proteasome does not stabilize mutant p53 but leads to its autophagic-mediated degradation. Therefore, we conclude that autophagy is a key mechanism for regulating the stability of several p53 mutants. We discuss plausible mechanisms involved in this newly identified degradation pathway as well as the possible role played by autophagy during tumor evolution driven by mutant p53.

Entities:  

Keywords:  autophagy; cancer; mutant; mutations; p53; proteasome; ubiquitin tumor

Mesh:

Substances:

Year:  2013        PMID: 23466706      PMCID: PMC3646859          DOI: 10.4161/cc.24128

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  50 in total

Review 1.  Links between mutant p53 and genomic instability.

Authors:  Walter Hanel; Ute M Moll
Journal:  J Cell Biochem       Date:  2012-02       Impact factor: 4.429

2.  Ubiquitination and degradation of mutant p53.

Authors:  Natalia Lukashchuk; Karen H Vousden
Journal:  Mol Cell Biol       Date:  2007-10-01       Impact factor: 4.272

3.  Mutant p53 protein localized in the cytoplasm inhibits autophagy.

Authors:  Eugenia Morselli; Ezgi Tasdemir; Maria Chiara Maiuri; Lorenzo Galluzzi; Oliver Kepp; Alfredo Criollo; José Miguel Vicencio; Thierry Soussi; Guido Kroemer
Journal:  Cell Cycle       Date:  2008-10-06       Impact factor: 4.534

4.  Gain of function of mutant p53 by coaggregation with multiple tumor suppressors.

Authors:  Jie Xu; Joke Reumers; José R Couceiro; Frederik De Smet; Rodrigo Gallardo; Stanislav Rudyak; Ann Cornelis; Jef Rozenski; Aleksandra Zwolinska; Jean-Christophe Marine; Diether Lambrechts; Young-Ah Suh; Frederic Rousseau; Joost Schymkowitz
Journal:  Nat Chem Biol       Date:  2011-03-27       Impact factor: 15.040

5.  Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop.

Authors:  Fabio Valenti; Francesca Fausti; Francesca Biagioni; Tal Shay; Giulia Fontemaggi; Eytan Domany; Michael B Yaffe; Sabrina Strano; Giovanni Blandino; Silvia Di Agostino
Journal:  Cell Cycle       Date:  2011-12-15       Impact factor: 4.534

6.  Noncanonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair.

Authors:  R M Hofmann; C M Pickart
Journal:  Cell       Date:  1999-03-05       Impact factor: 41.582

7.  Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide.

Authors:  Dennis J Goussetis; Elias Gounaris; Edward J Wu; Eliza Vakana; Bhumika Sharma; Matthew Bogyo; Jessica K Altman; Leonidas C Platanias
Journal:  Blood       Date:  2012-08-16       Impact factor: 22.113

8.  Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms.

Authors:  P A Futreal; P Söderkvist; J R Marks; J D Iglehart; C Cochran; J C Barrett; R W Wiseman
Journal:  Cancer Res       Date:  1992-05-01       Impact factor: 12.701

9.  Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs.

Authors:  Rosa Puca; Lavinia Nardinocchi; Manuela Porru; Amos J Simon; Gideon Rechavi; Carlo Leonetti; David Givol; Gabriella D'Orazi
Journal:  Cell Cycle       Date:  2011-05-15       Impact factor: 4.534

10.  Hsp90 regulates processing of NF-kappa B2 p100 involving protection of NF-kappa B-inducing kinase (NIK) from autophagy-mediated degradation.

Authors:  Guoliang Qing; Pengrong Yan; Zhaoxia Qu; Hudan Liu; Gutian Xiao
Journal:  Cell Res       Date:  2007-06       Impact factor: 25.617

View more
  40 in total

1.  N-terminal truncations of human bHLH transcription factor Twist1 leads to the formation of aggresomes.

Authors:  Gokulapriya Govindarajalu; Murugan Selvam; Elango Palchamy; Sudhakar Baluchamy
Journal:  Mol Cell Biochem       Date:  2017-08-04       Impact factor: 3.396

2.  Oncogenic pathways activated by pro-inflammatory cytokines promote mutant p53 stability: clue for novel anticancer therapies.

Authors:  Gabriella D'Orazi; Marco Cordani; Mara Cirone
Journal:  Cell Mol Life Sci       Date:  2020-10-17       Impact factor: 9.261

Review 3.  p53 in survival, death and metabolic health: a lifeguard with a licence to kill.

Authors:  Flore Kruiswijk; Christiaan F Labuschagne; Karen H Vousden
Journal:  Nat Rev Mol Cell Biol       Date:  2015-07       Impact factor: 94.444

Review 4.  Autophagy in malignant transformation and cancer progression.

Authors:  Lorenzo Galluzzi; Federico Pietrocola; José Manuel Bravo-San Pedro; Ravi K Amaravadi; Eric H Baehrecke; Francesco Cecconi; Patrice Codogno; Jayanta Debnath; David A Gewirtz; Vassiliki Karantza; Alec Kimmelman; Sharad Kumar; Beth Levine; Maria Chiara Maiuri; Seamus J Martin; Josef Penninger; Mauro Piacentini; David C Rubinsztein; Hans-Uwe Simon; Anne Simonsen; Andrew M Thorburn; Guillermo Velasco; Kevin M Ryan; Guido Kroemer
Journal:  EMBO J       Date:  2015-02-23       Impact factor: 11.598

5.  Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition.

Authors:  Marco Cordani; Elisa Oppici; Ilaria Dando; Elena Butturini; Elisa Dalla Pozza; Mercedes Nadal-Serrano; Jordi Oliver; Pilar Roca; Sofia Mariotto; Barbara Cellini; Giovanni Blandino; Marta Palmieri; Silvia Di Agostino; Massimo Donadelli
Journal:  Mol Oncol       Date:  2016-04-12       Impact factor: 6.603

Review 6.  Recent insights into apoptosis and toxic autophagy: The roles of MDA-7/IL-24, a multidimensional anti-cancer therapeutic.

Authors:  Luni Emdad; Praveen Bhoopathi; Sarmistha Talukdar; Anjan K Pradhan; Devanand Sarkar; Xiang-Yang Wang; Swadesh K Das; Paul B Fisher
Journal:  Semin Cancer Biol       Date:  2019-07-26       Impact factor: 15.707

7.  Dysfunction of X-linked inhibitor of apoptosis protein (XIAP) triggers neuropathological processes via altered p53 activity in Huntington's disease.

Authors:  Seung Jae Hyeon; Jinyoung Park; Junsang Yoo; Su-Hyun Kim; Yu Jin Hwang; Seung-Chan Kim; Tian Liu; Hyun Soo Shim; Yunha Kim; Yakdol Cho; Jiwan Woo; Key-Sun Kim; Richard H Myers; Hannah L Ryu; Neil W Kowall; Eun Joo Song; Eun Mi Hwang; Hyemyung Seo; Junghee Lee; Hoon Ryu
Journal:  Prog Neurobiol       Date:  2021-06-21       Impact factor: 11.685

Review 8.  Mechanisms of TP53 Pathway Inactivation in Embryonic and Somatic Cells-Relevance for Understanding (Germ Cell) Tumorigenesis.

Authors:  Dennis M Timmerman; Tessa L Remmers; Sanne Hillenius; Leendert H J Looijenga
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

Review 9.  Role of Dietary Antioxidants in p53-Mediated Cancer Chemoprevention and Tumor Suppression.

Authors:  J P Jose Merlin; H P Vasantha Rupasinghe; Graham Dellaire; Kieran Murphy
Journal:  Oxid Med Cell Longev       Date:  2021-06-26       Impact factor: 6.543

Review 10.  Mutant p53 in cancer: new functions and therapeutic opportunities.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.